Molecules and mechanisms of the graft-versus-leukaemia effect.
about
The human cathepsin H gene encodes two novel minor histocompatibility antigen epitopes restricted by HLA-A*3101 and -A*3303A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.T cell receptor gene therapy for cancerThe PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL.Cancer vaccines: the next generation of tools to monitor the anticancer immune response.Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Graft-versus-host disease biomarkers: omics and personalized medicineAdoptive T-cell therapy for LeukemiaSecondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restrictionGenetic barriers in transplantation medicineDonor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.Graft-versus-host disease: a surge of developmentsC19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.Two host factors regulate persistence of H7-specific T cells injected in tumor-bearing mice.A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit.Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.Immunotherapy in acute leukemiaTherapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.A polymorphism in the splice donor site of ZNF419 results in the novel renal cell carcinoma-associated minor histocompatibility antigen ZAPHIR.Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.Potential and limitation of HLA-based banking of human pluripotent stem cells for cell therapy.Polymorphisms in the base excision repair pathway and graft-versus-host disease.Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisitedPathogenesis and management of graft-versus-host disease.Frequencies of 10 autosomal minor histocompatibility antigens in Korean population and estimated disparities in unrelated hematopoietic stem cell transplantation.Both positive and negative effects on immune responses by expression of a second class II MHC molecule.Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning.An antigen produced by splicing of noncontiguous peptides in the reverse order.Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.Toll-like receptor polymorphisms in allogeneic hematopoietic cell transplantation.HDAC inhibition and graft versus host diseaseT-bet is critical for the development of acute graft-versus-host disease through controlling T cell differentiation and functionNonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
P2860
Q24296246-63E822BB-F3B2-424E-877D-DED452CDB2ACQ24536117-97B7C0B9-8E39-4F2D-86AF-7B74AB7E0411Q24634774-AEA425F2-3149-4429-9D3A-27C519D1956FQ24685666-AD5ACD3A-0EE0-49F9-8B53-9EF679ED3B97Q24814450-7EA07252-68CF-4BB9-B22F-9D2EDFD292BEQ26770391-D79CC812-24D9-4032-80C6-5AE0B9E9F175Q26824540-1EB93956-25C0-414F-9229-447CE56C9D8FQ27006934-21AC050C-31DB-4D82-BCE0-AC57E9E6E097Q27653882-6FEABFE7-C310-4556-8EFB-30EDCDFD8686Q27676136-21D5F160-7163-4F49-B4D5-FE5231269CD5Q28069956-B79939B9-EB95-4BB8-B8D5-7EAD27116FF5Q30558271-30882EEF-0A5A-419E-827E-AB4E778077CAQ33290423-1506CC16-FB01-4DF1-9661-6798B4D0A064Q33359498-710C13FA-3A5B-48FE-9A6F-8C070DF39761Q33398031-96F61810-4323-4CB5-A6B9-F3041C261A32Q33492227-2988C798-A148-42AB-881B-10E2F08AF583Q33627040-39A2392C-A522-4783-8689-7EF97098830CQ33634455-9CC190DC-DB14-4AFD-8B67-F244C5DEBFAEQ33709766-A394F293-43F4-42D0-8615-F35FE46D3E39Q33731552-FF430DBB-4BE0-4122-904A-340701B4D718Q33849560-8A5F295B-58DF-456E-BF1F-7F032110E05EQ33917224-E5CD8302-3BC6-4F71-8696-9B347911EF5EQ33931811-8C8F21ED-E3CA-4CF9-9927-9743EF485621Q33955292-2101D966-3423-4DFB-9164-35096716EE7CQ33967995-E7A75396-EC58-4BC8-9BBD-0811B70330F3Q33999335-0224107E-A7F3-432A-9E6F-494424A3DF43Q34063337-CF9CAFF3-3131-4EB7-B627-79D43FB2CC1DQ34065058-3A420978-FCC0-49CD-B8B3-40C4E1FCCE60Q34077479-41C4AEB6-E574-40D8-A712-F817AB9A1B55Q34093814-09C467C4-D9D4-4EF9-8526-4F527781D8D7Q34146648-4B00BD23-C279-45FB-A07C-4A29551F3815Q34163218-DA40EFD1-E2E6-426D-8323-9BD26B179AABQ34443622-4037DD11-A14A-452C-9963-4E67F68DF1F5Q34564542-6FC34253-9A1B-4AD6-8C1A-8A67B4AAAA6AQ34683729-05683A72-027E-460B-B754-44EAF91C2B3EQ34979770-898F8B6A-3866-4F8B-8AC9-95BCF5FF884AQ35016985-6C3AF7D7-F53C-42E4-AA2D-87C196A0C79DQ35041966-C9047D02-7EB1-4479-8952-C4DCA51B8ED1Q35211577-77920790-1824-499C-9982-2D77CA163FB6Q35546869-A0D4C4D2-F81E-4C93-8EF4-34BA5BC0A495
P2860
Molecules and mechanisms of the graft-versus-leukaemia effect.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Molecules and mechanisms of the graft-versus-leukaemia effect.
@ast
Molecules and mechanisms of the graft-versus-leukaemia effect.
@en
Molecules and mechanisms of the graft-versus-leukaemia effect.
@nl
type
label
Molecules and mechanisms of the graft-versus-leukaemia effect.
@ast
Molecules and mechanisms of the graft-versus-leukaemia effect.
@en
Molecules and mechanisms of the graft-versus-leukaemia effect.
@nl
prefLabel
Molecules and mechanisms of the graft-versus-leukaemia effect.
@ast
Molecules and mechanisms of the graft-versus-leukaemia effect.
@en
Molecules and mechanisms of the graft-versus-leukaemia effect.
@nl
P356
P1476
Molecules and mechanisms of the graft-versus-leukaemia effect.
@en
P2093
Marie Bleakley
Stanley R Riddell
P2888
P304
P356
10.1038/NRC1365
P407
P577
2004-05-01T00:00:00Z
P6179
1042309842